Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells

Journal of Neuro-Oncology

Volumn 40, Issue 2, 1998, Pages 137-150

  Arab, Sara ^a,b   Murakami, Masaji ^a   Dirks, Peter ^a   Boyd, Beth ^a,b   Hubbard, Sherri Lynn ^a   Lingwood, Clifford A ^a,b   Rutka, James T ^a,c  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

2 interferon; Globotriaosyl ceramide; Glycolipid receptor

Indexed keywords

GLOBOTRIAOSYLCERAMIDE; GLUCAN SYNTHASE; VEROTOXIN;

APOPTOSIS; ARTICLE; ASTROCYTOMA CELL; BRAIN TUMOR; CELL MEMBRANE; CELL ORGANELLE; CHROMATIN CONDENSATION; ELECTRON MICROSCOPY; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; HUMAN CELL; TUMOR CELL LINE; TUMOR GROWTH;

APOPTOSIS; ASTROCYTOMA; BACTERIAL TOXINS; BRAIN NEOPLASMS; CELL COUNT; CELL DIVISION; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYTOTOXINS; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HUMANS; MICROSCOPY, ELECTRON; SHIGA-LIKE TOXIN I;

EID: 0032420144     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006010019064     Document Type: Article

References (78)

1. Laws EJ, Taylor WF, Clifton MB, Okazaki H: Neurosurgical management of low grade astrocytomas of the cerebral hemispheres. J Neurosurg 61: 665-673, 1984
2. McCormack B, Miller D, Budzilovich G, Voorhees G, Ransohoff J: Treatment and survival of low-grade astrocytomas in adults. Neurosurg 31: 636-642, 1992
3. Muller W, Afra D, Schroder R: Supratentorial recurrences of gliomas: morphological studies with relation to time intervals in gliomas. Acta Neurochir 37: 75-91, 1977
4. O'Brien AD, Holmes RK: Shiga and Shiga-like toxins. Microbiol. Rev. 51: 206-220, 1987
5. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H: The association between hemolytic uremic syndrome and infection by Verotoxin-producing Escherichia coli. J. Infect. Dis. 151: 775-782, 1985
6. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, Blake PA, Cohen MC: Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 308: 681-685, 1983
7. Scotland SM, Smith HR, Rowe B: Two distinct toxins active on Vero cells from Escherichia coli O157:H7. Lancet ii: 885-886, 1985
8. Strockbine NA, Marques LRM, Newland JW, Smith HW, Holmes RK, O'Brien AD: Two toxin-converting phages from Escherichia coli O157:H7 Strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 53: 135-140, 1986
9. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara K, Igarashi K: Site of the action of a vero toxin (VT2) from Escherichia coli O157:H7 and a Shiga toxin on eukaryotic ribosomes. Eur J Biochem 171: 45-50, 1988
10. Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT: Pathogenesis of Shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163: 1391-1404, 1986
11. Mangeney M, Lingwood CA, Caillou B, Taga S, Tursz T, Wiels J. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 53: 5314-5319, 1993
12. Sandvig K, van Deurs B: Toxin-induced cell lysis: protection by 3-methyladenine and cycloheximide. Exp Cell Res 200: 253-262, 1992
13. Farkas-Himsley H, Rosen B, Hill R, Arab S, Lingwood CA: Bacterial colicin active against tumour cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci 92: 6996-7000, 1995
14. Lingwood CA, Yiu SCK: Glycolipid modification of α-interferon binding: sequence similarity between α-interferon receptor and the verotoxin (Shiga-like toxin) B-subunit. Biochem J 283: 25-26, 1992
15. Maloney MD, Lingwood CA: CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med 180: 191-201, 1994
16. Ghislain J, Lingwood CA, Fish EN: Evidence for glycosphingolipid modification of the type 1 IFN receptor. J Immunol 153: 3655-3663, 1994
17. Cohen A, Hannigan GE, Williams BRG, Lingwood CA: Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem 262: 17088-17099, 1987
18. Buckner J, Brown L, Kugler J, Cascino T, Krook J, Mailliard J, Kardinal C, Tschetter I, O'Fallon J, Scheithauer B: Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 82: 430-435, 1995
19. Naidu AK, Wiranowska M, Kori SH, Prockop PD, Kulkarni AP: Inhibition of human glioma cell proliferation and glulathione S-trase by ascorbyl esters and interferon. Anticancer Res 13: 1469-1475, 1993
20. Merchant RE, McVicar DW, Merchant LH, Yong HF: Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a preclinical trial. J Neurooncol 12: 75-83, 1992
21. Rutka JT, Giblin JR, Dougherty DY, Liu HC, McCulloch JR, Bell CW, Stern RS, Wilson CB, Rosenblum ML: Establishment and characterization of five cell lines derived from human malignant gliomas. Acta Neuropathol (Berl) 75: 92-103, 1987
22. Ponten J, MacIntyre H: Long-term culture of normal and neoplastic human glia. Pathol Microbiol Scand 81: 791-805, 1986
23. Westermark B, Ponten J, Hugosson R: Determinants for the establishment of permanent tissue culture lines from human gliomas. Acta Pathol Microbiol Scand 81: 791-805, 1973
24. Costello R, Delmaestro R: Human cerebral endothelium; isolation and characterization of cell derived from microvessels of non-neoplastic and malignant glial tissue. J Neurooncol 8: 231-243, 1990
25. Pintus C, Ransom J, Evans C: Endothelial cell growth supplement: a cell cloning factor that promotes the growth of monoclonal antibody producing hybridoma cells. J Immunol Meth 61: 195-200, 1983
26. Rutka JT, Kleppe-Hoifodt H, Emma DA, Giblin JR, Dougherty DV, McCulloch JR, DeArmond SJ, Rosenblum ML: Characterization of normal human brain cultures: Evidence for the outgrowth of leptomeningeal cells. Lab Invest 55: 71-85, 1986
27. Boulanger J, Huesca M, Arab S, Lingwood CA: Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands. Anal Biochem 217: 1-6, 1994
28. Petric M, Karmali MA, Richardson S, Cheung R: Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol Letts 41: 63-68, 1987
29. Head SC, Petric M, Richardson SE, Roscoe ME, Karmali M: Purification and characterization of verocytotoxin 2. FEMS Microbiol Lett 51: 211-216, 1988
30. Ramotar K, Boyd B, Tyrrell G, Gariepy J, Lingwood CA, Brunton J: Characterization of Shiga-like toxin 1 B subunit purified from overproducing clones of the SLT-1 B cistron. Biochem J 272: 805-811, 1990
31. Kueng W, Silber E, Eppenberger U: Quantification of cells cultured on 96-well plates. Anal Biochem 182: 16-19, 1989
32. Folch J, Lees M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-521, 1957
33. Yiu SCK, Lingwood CA: Polyisobutylmethacrylate modifies glycolipid binding specificity of verotoxin 1 in thin layer chromatogram overlay procedures. Anal Biochem 202: 188-192, 1992
34. Tylor I: A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem 28: 1021-1024, 1990
35. Nicoletti I, Migliorati C, Pagliacci M, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by pripidium iodide staining and flow cytometry. J Immunol Meth 139: 271-279, 1991
36. Falcieri E, Goggi P, Zamai L, Vitale M: Ultrastructural features of apoptosis. Scan Microscopy 8: 653-666, 1994
37. Anderson KM, Seed TM, Peng J, Jajeh A, Meng J, Harris JE: Morphologic changes of apoptosis induced in human chronic myelogenous leukemia 'blast' cells by SC41661A (Searle), a selective inhibitor of 5-lipoxygenase. Scanning Miscoscopy 8: 675-686, 1994
38. Head S, Karmali M, Lingwood CA: Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits: Evidence for R subunit modulation of A subunit function. J Biol Chem 266: 3617-3621, 1991
39. Lindgren SW, Samuel JE, Schmitt CK, O'Brien AD: The specific activities of Shiga-likec toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coil differ when measured by vero cell cytotoxicity but not by mouse lethality. Infect Immun 62: 623-631, 1994
40. Lieberman E, Heuser E, Donnel G, Landing B, Hammond G: Hemolytic Uremic Syndrome. Clinical and pathological considerations. N Engl J Med 275: 227-236, 1966
41. Rowe P, Orrbine E, Wells G, McLaine P: Epidemiology of the hemolytic uremic syndrome in Canadian children from 1986-1988. J Pediat 119: 218-224, 1991
42. Karmali MA: Infection by Verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 2: 15-38, 1989
43. Lingwood CA: Verotoxins and their glycolipid receptors. In: Bell R, Hannun YA and Merrill Jr A (eds) Advanced in lipid research. Academic Press, San Diego, 1993, pp 189-212
44. Saxena SK, O'Brien AD, Ackerman EJ; Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA from microinjecled into Xenopus oocytes. J Biol Chem 264: 596-601, 1989
45. Wiels J, Mangeney M, Tétaud C, Tursz T: Sequential shifts in the three major glycosphingolipid series are associated with B cell differentiation. Int Immunol 3: 1289-1300, 1991
46. Fyfe G, Cebra-Thomas JA, Mustain E, Davie JM, Alley CD, Nahm MH: Subpopulations of B lymphocytes in germinal centers. J Immunol 139: 2187-2194, 1987
47. Balana A, Wiels J, Tetaud C, Mishal Z, Tursz T: Induction of cell differentiation in Burkitt lymphoma lines. BLA: A glycolipid marker of B-cell differentiation. Int J Cancer 36: 453-460, 1985
48. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J: CD77: an antigen of germinal center B cells entering apoptosis. Eur J Immunol 21: 1131-1140, 1991
49. Murray LJ, Habeshaw JA, Wiels J, Greaves MF: Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer 36: 561-565, 1985
50. Farkas-Himsley H, Cheung R, Thompkins WAF: Selective antitumor agents: Bacteriocins from gram-negative bacteria. IRCS Med Sci 3: 148, 1975
51. Hill RP, Farkas-Himsley H: Studies on the efficacy of bacteriocin (colicin) treatment of lung metastases of a murine fibrosarcorna. Treatment of metastases: Problems and perspectives 133-136, 1985
52. Hill RP, Farkas-Himsley H: Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. Cancer Res 51: 1359-1365, 1991
53. Arab S, Russel E, Chapman W, Rosen B, Lingwood C: Expression of the Verotoxin receptor glycolipid, globotriaosyl ceramide in Ovarian Hyperplasias. Oncol Res [in press]
54. Mannori G, Cecconi O, Mugnai G, Ruggieri S: Role of glycolipids in the metastatic process: Characteristics neutral glycolipids in clones with different metastatic potentials isolated from a murine fibrosarcoma cell line. Int J Cancer 45: 984-988, 1990
55. Li S-C, Kundu SK, Degasperi R, Li Y-T: Accumulation of globotriaosylceramide in a case of leiomyosarcoma. Biochem J 240: 925-927, 1986
56. Wenk J, Andrews PW, Casper J, Hata J-I, Pera MF, von Keitz A, Damjanov I, Fenderson BA: Glycolipids of germ cell tumors: extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int J Cancer 58: 108-115, 1994
57. Cohen A, Madrid-Marina V, Estrov Z, Freedman M, Lingwood CA, Dosch H-M: Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int. Immunol 2: 1-8, 1990
58. Arab S, Lingwood C: Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to Verotoxin: sodium butyrate or selection of drug resistance may induce nuclear toxin targeting via globotriosyl ceramide fatty acid isoform traffic. [submitted]
59. Colamonici O, Porterfield B, Domanski P, Handa R, Flex S, Samuel C, Pine R, Diaz M: Ligand-independent anti-oncogenic activity of there alpha subunit of the type 1 interferon receptor. J Biol Chem 269: 1994
60. Inward CD, Williams J, Chant I, Crocker J, Milford DV, Rose PL, Taylor CM: Verocytotoxin-1 induces apoptosis in vero cells. J Infect 30: 213-218, 1995
61. Cotter TG, Lennon SV, Glynn JG, Martin SJ: Cell death via apoptosis and its relationship to growth. Development and differentiation of both tumor and normal cells. Anticancer Res 10: 1153-1159, 1990
62. Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 79: 189-192, 1994
63. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human myclogenous leukemia cells by etoposide, camtothectin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870-5878, 1989
64. Barry M, Behink CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharma 40: 2353-2362, 1990
65. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 1992
66. Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG: Shiga toxin-associated hemolytic uremic syndrome: Interleukin-1β enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 61: 3886-3891, 1993
67. Louise CB, Obrig TG: Shiga toxin-associated hemolytic uremic Syndrome: combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Inf Imm 60: 1536-1543, 1992
68. Obrig T, Louise C, Lingwood C, Boyd B, Barley-Maloney L. Daniel T: Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 268: 15484-15488, 1993
69. van der Kar NCAJ, Monnens LAH, Karmali M, van Hinsbergh VWM: Tumor necrosis factor and interleukin-1 induce expression of the verotoxin receptor globotriaosyl ceramide on human endothelial cells: implications for the pathogenesis of the Hemolytic Uremic Syndrome. Blood 80: 2755-2764, 1992
70. van der Kar NCJ, Kooistra T, Vermeer M, Lesslauer W, Monnens LAH, van Hinsbergh VWM: Tumor necrosis factor a induces endothelial galactosyl transferase activity and verocytotoxin receptors. Role of specific tumor necrosis factor receptors and protein kinase C. Blood 85: 734-743, 1995
71. Murakami H, Lam Z, Furie BC, Reinhold VN, Asano T, Furie B: Sulfated glycolipids are the platelet autoantigens for human platelet-binding monoclonal anti-DNA autoantibodies. J Biol Chem 266: 15414-15419, 1991
72. Piazza G, Kulckak Rahm A, Krutzsch M, Sperl G, Paranka N, Gross P, Brendel K, Burt R, Alberts D, Pamukcu R, Ahnen D: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116, 1995
73. Obrig TG, Vecchio PJD, Brown JE, Moran TP, Rowland BM, Judge TK, Rothman SW: Direct cytotoxic action of shiga toxin on human vascular endothelial cells. Infect Immun 56: 2373-2378, 1988
74. Pudymaitis A, Lingwood CA: Susceptibility to verotoxin as a function of the cell cycle. J Cell Physiol 150: 632-639, 1992
75. Korbury CJ, Nurse P: Control of higher eukaryote cell cycle by p34 homologues. Biochim Biophys Acta 989: 85-95, 1989
76. Wage Y, Szekely L, Okan I, Klein G, Wiman KG: Wild type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc induced T-cell lymphoma line. Oncogene 8: 3427-3432, 1993
77. Vaux DL, Haecker G, Strasser A: An evolutionary perspective on apoptosis. Cell 76: 777-779, 1994
78. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating cells via p53-independent mechanisms inhibited by bcl-2. Cell 79: 189-192, 1994